SCHEMBL3668076

SCHEMBL3668076

COCOc1ccc(C=CC=C2C(=O)N(c3ccccc3)N=C2C)cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 13/20 0.65
L3MBTL1 Q9Y468 6/20 0.65
POLB P06746 3/20 0.63
MAPT P10636 8/20 0.61
MAPK1 P28482 6/20 0.61
ALDH1A1 P00352 6/20 0.61
HTT P42858 5/20 0.61
TDP1 Q9NUW8 4/20 0.61
LMNA P02545 3/20 0.61
MEN1 O00255 9/20 0.57
PKM P14618 3/20 0.57
OPRK1 P41145 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
AMY1A P0DUB6 3/20 0.56
HPGD P15428 2/20 0.55
MDM2 Q00987 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
GPR55 Q9Y2T6 1/20 0.52
GAA P10253 2/20 0.50
CA1 P00915 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13572441 1.00 KMT2A (0.65) KMT2AL3MBTL1POLBMAPTMAPK1
SCHEMBL3739407 0.84 KMT2A (0.66) KMT2AL3MBTL1POLBMAPTMAPK1
SCHEMBL4257062 0.84 KMT2A (0.76) KMT2AL3MBTL1POLBMAPTALDH1A1
SCHEMBL4268975 0.84 KMT2A (0.76) KMT2AL3MBTL1POLBMAPTALDH1A1
SCHEMBL18253196 0.79 KMT2A (0.79) KMT2AL3MBTL1POLBMAPTMAPK1
SCHEMBL4144051 0.77 KMT2A (0.83) KMT2AL3MBTL1POLBMAPTALDH1A1
SCHEMBL4144049 0.77 KMT2A (0.83) KMT2AL3MBTL1POLBMAPTALDH1A1
SCHEMBL4257118 0.73 APP (0.48) KMT2AL3MBTL1POLBMAPTALDH1A1
SCHEMBL4257121 0.73 APP (0.48) KMT2AL3MBTL1POLBMAPTALDH1A1
SCHEMBL16081336 0.73 MAPT (1.00) KMT2AL3MBTL1POLBMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4425628-B2 2010-03-03 JP claimed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP claimed
JP-2005505519-A 2005-02-24 JP claimed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP claimed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US claimed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO claimed
US-7629375-B2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2009-12-08 US disclosed
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2006-08-10 US disclosed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP disclosed
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER INC. 2005-06-30 US disclosed
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2005-05-26 US disclosed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP disclosed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US disclosed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 KMT2A 4665/4885L3MBTL1 3011/4885POLB 1618/4885
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 KMT2A 4665/4885L3MBTL1 3011/4885POLB 1618/4885
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 KMT2A 4665/4885L3MBTL1 3011/4885POLB 1618/4885
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 KMT2A 4665/4885L3MBTL1 3011/4885POLB 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.